PTC Therapeutics Future Growth
Future criteria checks 0/6
PTC Therapeutics is forecast to grow earnings and revenue by 46.3% and 5.5% per annum respectively while EPS is expected to grow by 44.5% per annum.
Key information
46.3%
Earnings growth rate
44.5%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 5.5% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 09
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
Sep 12Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues
Jun 28PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna
May 22Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%
May 22PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
May 14PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Mar 03PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options
Feb 11An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Jun 23Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price
May 18An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Mar 02PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.
Oct 19PTC Therapeutics betas topline expectations, strengthens commercial portfolio
Aug 05PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder
Jul 20PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price
Jun 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 835 | -158 | 94 | 207 | 12 |
| 12/31/2025 | 721 | -317 | 22 | 2 | 14 |
| 12/31/2024 | 784 | -391 | -202 | -181 | 14 |
| 9/30/2024 | 901 | -453 | -274 | -178 | N/A |
| 6/30/2024 | 900 | -480 | -230 | -115 | N/A |
| 3/31/2024 | 928 | -579 | -199 | -58 | N/A |
| 12/31/2023 | 938 | -627 | -279 | -158 | N/A |
| 9/30/2023 | 798 | -642 | -343 | -224 | N/A |
| 6/30/2023 | 819 | -618 | -364 | -248 | N/A |
| 3/31/2023 | 770 | -571 | -403 | -289 | N/A |
| 12/31/2022 | 699 | -559 | -509 | -357 | N/A |
| 9/30/2022 | 697 | -531 | -409 | -260 | N/A |
| 6/30/2022 | 618 | -556 | -422 | -273 | N/A |
| 3/31/2022 | 569 | -522 | -395 | -249 | N/A |
| 12/31/2021 | 539 | -524 | -337 | -251 | N/A |
| 9/30/2021 | 492 | -455 | -327 | -247 | N/A |
| 6/30/2021 | 472 | -391 | -250 | -169 | N/A |
| 3/31/2021 | 430 | -454 | -271 | -213 | N/A |
| 12/31/2020 | 381 | -438 | -250 | -194 | N/A |
| 9/30/2020 | 358 | -441 | -193 | -140 | N/A |
| 6/30/2020 | 311 | -432 | -221 | -182 | N/A |
| 3/31/2020 | 322 | -292 | -198 | -138 | N/A |
| 12/31/2019 | 307 | -252 | -144 | -99 | N/A |
| 9/30/2019 | 297 | -222 | -142 | -104 | N/A |
| 6/30/2019 | 279 | -213 | -116 | -85 | N/A |
| 3/31/2019 | 262 | -181 | -72 | -54 | N/A |
| 12/31/2018 | 265 | -128 | -43 | -28 | N/A |
| 9/30/2018 | 256 | -78 | 0 | 9 | N/A |
| 6/30/2018 | 245 | -61 | N/A | -10 | N/A |
| 3/31/2018 | 224 | -69 | N/A | 3 | N/A |
| 12/31/2017 | 194 | -79 | N/A | -10 | N/A |
| 9/30/2017 | 142 | -107 | N/A | -45 | N/A |
| 6/30/2017 | 123 | -108 | N/A | -53 | N/A |
| 3/31/2017 | 90 | -130 | N/A | -91 | N/A |
| 12/31/2016 | 83 | -142 | N/A | -104 | N/A |
| 9/30/2016 | 70 | -166 | N/A | -121 | N/A |
| 6/30/2016 | 57 | -174 | N/A | -124 | N/A |
| 3/31/2016 | 48 | -174 | N/A | -129 | N/A |
| 12/31/2015 | 37 | -170 | N/A | -124 | N/A |
| 9/30/2015 | 37 | -147 | N/A | -102 | N/A |
| 6/30/2015 | 29 | -131 | N/A | -91 | N/A |
| 3/31/2015 | 24 | -118 | N/A | -80 | N/A |
| 12/31/2014 | 25 | -94 | N/A | -57 | N/A |
| 9/30/2014 | 17 | -84 | N/A | -64 | N/A |
| 6/30/2014 | 32 | -62 | N/A | -52 | N/A |
| 3/31/2014 | 37 | -51 | N/A | -53 | N/A |
| 12/31/2013 | 35 | -66 | N/A | -47 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PTCT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PTCT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PTCT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PTCT's revenue (5.5% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: PTCT's revenue (5.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PTCT's Return on Equity is forecast to be high in 3 years time